Primary sclerosing cholangitis
Conditions
Interventions
1 MZR
Daily intake of mizoribine once before breakfast. Dose adjustment is done to achieve a blood concentration level over 3.0 microg/ml at 3 hour after meal.
2)AZT
Daily intake of azathioprine once
Sponsors
Tajiri Hitoshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Primary sclerosing cholangitis 2. No condition on primary disease. 3.Patients age is 18 years old from 3 years old at the agreement acquisition. 3.No condition on primary disease. 4.When there are complications such as an esophagus varix, the cirrhosis, it depends on a chief physician judgment 5.Written informed consent after adequate explanation and acceptance.
Exclusion criteria
Exclusion criteria: 1.History of hypersensitivity to any ingredients of Bredinin, Imuran, or Azanin. 2.Patients with WBC less than 3000/m3. 3.Patients with severe degree of allergic diseases. 4.Patients who are assessed to be ineligible for this study by the principle investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver function tests including AST, ALT, gamma-GTP, and bilirubin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in liver histology Improvement in MRCP findings Physical condition Adverse effects, abnormal laboratory tests. | — |
Contacts
Public ContactHitoshi Tajiri
KINDAI UNIVERSITY
Outcome results
None listed